Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Crysvita (burosumab-twza) for Treating X–Linked Hypophosphatemia

Drug Name

Crysvita® (burosumab-twza)

Developer

Kyowa Hakko Kirin and Ultragenyx Pharmaceutical

Therapy Class

Antibody

Product Description

Fibroblast growth factor 23 (FGF23) blocking antibody

Current Indication

X-linked hypophosphatemia (XLH)

Market Sector

Genetics

Development Status

Approved in the US, Europe, and Canada
Expand

Free download worth over $5000
Download our 2019 Technology, Media and Telecoms Predictions Report

Worth up to $5,850

In this report, we look at the 30 big tech themes for 2019, identifying winners and losers for each theme. This report will impact all industries helping:

  • CEOs/Senior Staff: in all industries understand the disruptive threats to their competitive landscape
  • Investors: Helps fund managers focus their time on the most interesting investment opportunities in global TM

Go Top